Figure S1. Trial profile.

Consort figure from Polyak et al., (Ref: 16) showing study retention. A total of 490 participants (98%) were retained to the end of scheduled follow-up. Participants randomized to the CTX continuation arm self-reported that they took CTX every day in the past week at 90.5% of follow-up visits.